Orion Oyj Series A | Income Statement

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,010
1,020
1,014
1,072
1,088
978
Cost of Goods Sold (COGS) incl. D&A
413
422
425
440
462
406
Gross Income
596
598
589
632
626
573
SG&A Expense
328
322
324
343
334
324
EBIT
268
275
265
289
292
249
Unusual Expense
-
3
2
1
1
-
Non Operating Income/Expense
2
1
4
26
2
4
Interest Expense
4
6
6
5
6
5
Pretax Income
264
267
262
311
287
248
Income Tax
58
57
54
62
61
51
Equity in Affiliates
-
-
-
-
-
-
Consolidated Net Income
206
211
208
249
226
197
Net Income
206
211
208
249
226
197
Net Income After Extraordinaries
206
211
208
249
226
65
Net Income Available to Common
206
211
208
249
226
202
EPS (Basic)
1.46
1.50
1.48
1.77
1.61
2.35
Basic Shares Outstanding
141
141
141
141
141
141
EPS (Diluted)
1.46
1.50
1.48
1.77
1.61
2.35
Diluted Shares Outstanding
141
141
141
141
141
141
EBITDA
305
313
305
329
333
290
Other Operating Expense
-
-
1
-
-
-
Non-Operating Interest Income
-
1
-
-
1
-

About Orion Oyj

View Profile
Address
Orionintie 1A
Espoo UU 02200
Finland
Employees -
Website http://www.orion.fi
Updated 07/08/2019
Orion Oyj engages in the development of pharmaceutical and diagnostic test. It develops, manufactures, and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Its pharmaceutical research and development focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.